For citations:
Zeltyn-Abramov E.M., Lysenko M.A., Frolova N.F., Markova T.N., Belavina N.I., Klochkova N.N., Kondrashkina S.V., Iskhakov R.T., Ushakova A.I. Risk factors of adverse outcome of COVID-19 and experience of Tocilizumab administration in patients on maintenance hemodialysis due to diabetic kidney disease. Diabetes mellitus. 2021;24(1):17-31. (In Russ.) https://doi.org/10.14341/DM12688
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
